# **HDFC Life Insurance Company Ltd**



KRChoksey Institutional

India Equity	Institutional Re	esearch II Resul	t Update – Q2FY21	II 21 <sup>st</sup> Oct, 2020	Page 2
HDFC	Life Ins	urance Co.	Ltd.	Soft performance led	by lower loan origination and volume
CMP <b>INR 571</b>	Target INR 704	Potential Upside <b>23-4</b> %	Market Cap (INR C <b>INR 115,311</b>	r) Recommendation BUY	Sector <b>Life Insurance</b>

## **Result Highlights:**

•Total Gross Written Premium (GWP) grew 34.8% YoY/73.7% QoQ on the back of strong new business and healthy renewals.

•HDFC Life market share (on New Business Premium (NBP) basis) grew 235 bps to 18% from 15% in H1FY21. Its market share among private players is 27.4%.

•In Q2FY21, channel mix on NBP basis is 60% for bancassurance channel, 13% for agency channel, 6% for brokers and 21% for direct. All channel except direct gained by 100 bps at the cost of direct.

•Solvency ratio rose to 203% on account of Sub debt of INR 600 Cr and improved equity markets.

•Net worth improved by 23%YoY to INR 7,790 Cr. Embedded Value increased to INR 23,330 Cr, higher by 16% YoY.

MARKET DATA	
Shares outs (Mn)	202
Equity Cp (INR Mn)	7,820
Mkt Cap (INR Mn)	115,311
52 Wk H/L (INR)	647/340
Volume Avg (3m K)	3,000
Face Value (INR)	10.0
Bloomberg Code	HDFCLIFE: IN

SHARE	PRICE	PERFO	RMANCE
-------	-------	-------	--------



#### **MARKET INFO**

ANALYST

SENSEX	40,544
NIFTY	11,896

## SHARE HOLDING PATTERN (%)

Particulars	Sep20	Jun-20	Mar-20
Promoters	60.4	60.4	63.7
FIIs	23.4	23.6	21.1
DIIs	5.3	5.4	4.5
Others	10.9	10.6	10.7
Total	100	100	100

Parvati Rai, head-research@krchoksey.com, +91-22-6696 5413

KEY FINANCIALS					
Particulars (INR Crores)	FY18	FY19	FY20	FY21E	FY22E
GWP	23,564	29,186	32,707	37,206	41,246
PAT	1,109	1,277	1,295	1,136	1,061
EPS (INR/Share)	5.51	6.33	6.42	5.63	5.25
NBP-APE	5,400	6,049	7,164	8,039	9,184
VNB	1,282	1,537	1,919	2,090	2,415
VNB Margin (%)	23%	25%	26%	26%	26%
EVPS (INR/Share)	75.6	90.7	102.3	130.9	151.3
Source: Company, KRChoksey Research					

### Premium growth returns strongly:

The GWP grew at a robust ~35% YoY/74% QoQ driven by an improvement in individual premium. The opening of the economy ensured improved business momentum. The NBP grew 23% YoY/77% QoQ against a degrowth of 25% YoY /43% QoQ in the last quarter. The insurer gained significant market share at ~23.3% from 20.7% last quarter. Its 13<sup>th</sup>, 25<sup>th</sup>, and 49<sup>th</sup> month persistency rose by ~100-200 bps QoQ and the others remained stable. The renewal premium also rose 21% YOY/33% QoQ. The share of all other channels of distribution rose by ~100-200 bps at the cost of direct as businesses opened. Solvency ratio rose to 203% on account of Sub debt of INR 600 Cr and improved valuations in the equity markets.

#### VNB improves by 80 bps on shift in product mix:

The margins improved to 25.1% vs 24.3% last quarter, higher by 80 bps QoQ. This is backed by 22% growth in Value of New Business (VNB) in Q2FY21 to INR 548 Cr. The growth in H1FY21 is 40% YoY, higher optically on account of weak business in Q1FY21 despite a high base. The sequential improvement is on account of the shift in product mix towards Par, savings product, and individual protection. The share of Par grew by ~200-300 bps in the product mix even as credit protection has lagged.

#### Opening of the economy improves momentum across channels and persistency:

The share of various distribution channels rose by ~100-200 bps at the cost of direct. The distribution mix between Banca/broker/agency/direct is 60%/6%/13%/21% vs 59%/5%/12%/24% last quarter. The early months persistency and  $49^{th}$  month persistency across channels rose by ~100-200 bps, another positive. The overall persistency was 88%/79%/69%/66%/53% vs 87%/77%/69%/65%/53% for 13th/25th/37th/49th/61st month respectively. This augurs very well for the company and is likely to aid in continued improvement in business momentum.



APE CAGR between FY20 and FY22E 12.2%

#### VNB CAGR between FY20 and FY22E

KRChoksey Research is also available on Bloomberg KRCS<GO> Thomson Reuters, Factset and Capital IQ Phone: +91-22-6696 5555, Fax: +91-22-6691 9576 www.krchoksey.com India Equity Institutional Research II

Result Update – Q2FY21

Page 3

# HDFC Life Insurance Co. Ltd.


#### Key Concall highlights:

(i) Opening in economy, improved activity, improvement in household income has improved activity for insurance and individual business esp. protection. (ii) The Covid claims are within estimates and Non Covid claims are lower. It has received 418 Covid claim and 50 non Covid claims. The provision of INR 41 Cr is sufficient for risk to mortality as other claims are lower. (iii) INR 600 Cr in subdebt has augmented solvency by 14%. The bank raised this to be ready for growth. (iv) It has launched Video based sale enabling product in T-II and T-III cities. It has extended the hybrid model. (v) Maintain cautious outlook given the second wave in Europe. (vi) There is likely to be fresh demand for insurance. (vii) New guidelines to reduce aversion to serve the low-ticket protection segment. (viii) Economic variance has been changed on account of volatility in the yield curve. (ix) Reinsurance price passthrough risk is behind. (x) It has 65-70% Market share in HDFC Bank. (xi) The strain is higher on account of mix but back book surplus (grew 10%) and unwind is helpful.

#### Valuation and view

HDFC Life has delivered a robust business performance despite the weak market conditions. Its strength in distribution and product mix augurs very well for its business momentum and we expect it to continue to gain market share and improve margins. The flexibility across products gives it ability to grow without material hurdles. Its 65% market share in HDFC bank is a differentiator especially considering this is one of the banks that has recovered from the pandemic the fastest. While the claim payout is likely to be higher, offsetting it with improved persistency, favourable margin product growth, safety of GoI investments amidst falling interest rates augurs well for CAGR 12.2% in VNB and 21.6% in EV over FY20-22E.

The franchise, product and distribution culminates into high quality growth prospects, commanding higher valuation premium. We assign a 4.6x P/EV on FY22E EVPS of INR 151.3 and a higher VNB multiple of 48x on FY22E to arrive at a weighted average TP of INR 704 per share for HDFC Life (50:50 weights on the P-EV and appraisal value methodology); indicating an upside of 23.4% over CMP. Accordingly, we reiterate "BUY" rating on the shares of HDFC Life.



Parvati Rai, head-research@krchoksey.com, +91-22-6696 5413

KRChoksey Research is also available on Bloomberg KRCS<GO> Thomson Reuters, Factset and Capital IQ Phone: +91-22-6696 5555, Fax: +91-22-6691 9576 www.krchoksey.com Result Update – Q2FY21

#### **KEY FINANCIALS**

#### Exhibit 1: Revenue Account/Policy Holder's Account

Particulars (INR Cr.)	FY18	FY19	FY20	FY21E	FY22E
Gross premiums	23,564	29,186	32,707	37,206	41,246
Reinsurance ceded	193	262	483	744	362
Net premiums	23,371	28,924	32,224	36,461	40,884
Net income from investments	8,863	9,511	-2,962	8,700	8,002
Total income	32,234	38,436	29,261	45,162	48,886
Commission expenses	1,075	1,132	1,491	1,693	1,785
Operating expenses	3,159	3,801	4,267	4,334	4,541
Servive tax on linked charges	297	340	353	348	386
Operating profit	27,703	33,163	23,150	38,788	42,175
Benefits paid (net)	12,895	13,415	18,173	20,536	21,562
Change in reserves	13,322	17,507	2,441	15,000	15,000
Interim Bonuses Paid	217	574	848	900	900
Surplus / (Deficit) Before tax	1,269	1,667	1,688	2,352	4,712
Provision For Tax & Others	175	317	716	929	1,260
Surplus / (Deficit) After tax	1,095	1,349	971	1,423	3,453

Source: Company, KRChoksey Research

#### Exhibit 2: Premium Schedule

Particulars (INR Cr.)	FY18	FY19	FY20	FY21E	FY22E
First year premiums	4,738	5,058	6,044	6,830	7,855
Single premiums	6,611	9,913	11,194	12,090	13,299
New business premium (NBP)	11,350	14,971	17,238	18,920	21,153
NBP growth (%)	30.5%	31.9%	15.1%	9.8%	11.8%
Renewal premiums	12,215	14,215	15,468	18,286	20,093
Renewal premiums growth (%)	13.6%	16.4%	8.8%	18.2%	9.9%
Total premiums	23,564	29,186	32,707	37,206	41,246
Total premium growth (%)	21.2%	23.9%	12.1%	13.8%	10.9%
NBP - APE	5,400	6,049	7,164	8,039	9,184
NBP - APE growth (%)	32.2%	12.0%	1 <b>8.</b> 4%	12.2%	14.2%

Source: Company, KRChoksey Research

## Exhibit 3: Profit & Loss Account/Shareholder's Account

Particulars (INR Cr.)	FY18	FY19	FY20	FY21E	FY22E
Transfer from Technical account	1,002	1,207	1,191	1,423	1,528
Income from investments & other income	293	429	456	20	20
Total income	1,295	1,636	1,648	1,443	1,548
Total expenses	169	346	336	289	466
РВТ	1,127	1,290	1,312	1,154	1,082
Provision for tax	18	13	16	17	22
PAT	1,109	1,277	1,295	1,136	1,061

Source: Company, KRChoksey Research

II 21<sup>st</sup> Oct, 2020

# HDFC Life Insurance Co. Ltd.

#### Exhibit 4: Balance Sheet

Particulars (INR Cr.)	FY18	FY19	FY20	FY21E	FY22E
Sources of funds					
Share capital	2,012	2,017	2,019	2,019	2,019
Share application money	1	0	6	0	0
Reserves and surplus	2,706	3,641	4,968	6,004	6,764
Fair value change account - net	30	-3	-192	-3	-3
Shareholders' fund	4,749	5,656	6,800	8,020	8,780
Liabilities (Policyholder's Funds)	308	171	171	171	171
Fair value change account - net	622	1,112	50	52	54
Policy liabilities	42,319	53,635	65,271	56,431	58,688
Provision for linked liabilities	46,565	51,449	54,377	54,131	56,297
Credit/[debit] fair value change account	8,033	9,072	-3,533	9,545	9,927
Discontinued due to non-payment of premium	2,587	2,856	3,338	3,471	3,610
Sub-Total	1,00,127	1,18,124	1,19,503	1,24,283	1,31,740
Funds for future Appropriations	959	1,103	883	883	883
Total Sources of Funds	1,05,835	1,24,883	1,27,185	1,33,185	1,41,403
Application of Funds					
Investments					
- Shareholders'	4,070	5,050	5,855	7,905	10,672
- Policyholders'	45,347	57,124	67,189	77,267	88,857
Asset held to cover linked liabilities	57,185	63,377	54,182	62,309	71,656
Loans	19	80	299	48	48
Fixed assets - net block	341	333	330	425	425
Net current assets	-1,128	-1,082	-670	-14,769	-30,254
Total Applications of Funds	1,05,835	1,24,883	1,27,185	1,33,185	1,41,403

EV Calculation (INR Cr.)	FY18	FY19	FY20	FY21E	FY22E
Opening EV	12,471	15,216	18,300	20,650	26,363
Unwind	1,044	1,300	1,367	1,543	1,845
VNB (or NBAP)	1,282	1,537	1,919	2,090	2,415
Operating variance	357	419	148	180	200
EV Operating Profit (EVOP)	2,683	3,256	3,314	3,813	4,461
Non-operating variance	259	259	-1,003	2,000	-200
EV Profit	2,942	3,515	2,311	5,813	4,261
Net capital injection	-196	-396	38	-100	-100
Closing EV	15,217	18,300	20,650	26,363	30,524

Source: Company, KRChoksey Research

Key Financials (INR Cr.)	FY18	FY19	FY20	FY21E	FY22E
Total premium	23,564	29,186	32,707	37,206	41,246
Net premium earned	23,371	28,924	32,224	36,461	40,884
NBP-APE	5,400	6,049	7,164	8,039	9,184
Combined Ratio	19.4%	18.2%	19.0%	17.5%	16.4%
Surplus/(Deficit)	1,269	1,667	1,688	2,352	4,712
VNB margin (%)	23.2%	24.6%	25.9%	26.0%	26.3%
PAT	1,109	1,277	1,295	1,136	1,061
EPS (Rs.)	5.51	6.33	6.42	5.63	5.25
EVPS (Rs.)	75.64	90.71	102.29	130.90	151.30
RoEV (%)	21.5%	21.4%	18.1%	18.5%	16.9%
RoE (%)	23.4%	22.6%	19.0%	14.2%	12.1%

Source: Company, KRChoksey Research

India Equity Institutional Research II

Result Update – Q2FY21

II 21<sup>st</sup> Oct, 2020

Page 6

# HDFC Life Insurance Co. Ltd.

HDFC Life Insurance				Rating Legend (Expected over a 12-month period)	
Date	CMP (INR)	TP (INR)	Recommendatio n	Our Rating	Upside
				Buy	More than 15%
21-Oct-20	571	704	BUY	Accumulate	5% – 15%
24-Sep-20	580	704	BUY	Hold	0 – 5%
28-Apr-20	486	600	BUY		⊂ <b>3</b> ‰
08-Apr-20	477	604	BUY	Reduce	-5% – 0
24-Jan-20	608	730	BUY	Sell	Less than – 5%

#### ANALYST CERTIFICATION:

I, Parvati Rai (MBA-Finance, M.com), Head Research, author and the name subscribed to this report, hereby certify that all of the views expressed in this research report accurately reflect my views about the subject issuer(s) or securities. I also certify that no part of our compensation was, is, or will be directly or indirectly related to the specific recommendation(s) or view(s) in this report.

#### Terms & Conditions and other disclosures:

KRChoksey Shares and Securities Pvt. Ltd (hereinafter referred to as KRCSSPL) is a registered member of National Stock Exchange of India Limited and Bombay Stock Exchange Limited. KRCSSPL is a registered Research Entity vides SEBI Registration No. INH000001295 under SEBI (Research Analyst) Regulations, 2014.

We submit that no material disciplinary action has been taken on KRCSSPL and its associates (Group Companies) by any Regulatory Authority impacting Equity Research Analysis activities.

KRCSSPL prohibits its analysts, persons reporting to analysts and their relatives from maintaining a financial interest in the securities or derivatives of any companies that the analyst covers. The information and opinions in this report have been prepared by KRCSSPL and are subject to change without any notice. The report and information contained herein is strictly confidential and meant solely for the selected recipient and may not be altered in any way, transmitted to, copied or distributed, in part or in whole, to any other person or to the media or reproduced in any form, without prior written consent of KRCSSPL. While we would endeavor to update the information nerein on a reasonable basis, KRCSSPL is not under any obligation to update the information. Also, there may be regulatory, compliance or other reasons that may prevent KRCSSPL form doing so. Non-rated securities indicate that rating on a particular security has been suspended temporarily and such suspension is in compliance with applicable regulations and/or KRCSSPL policies, in circumstances where KRCSSPL might be acting in an advisory capacity to this company, or in certain other circumstances.

This report is based on information obtained from public sources and sources believed to be reliable, but no independent verification has been made nor is its accuracy or completeness guaranteed. This report and information herein is solely for informational purpose and shall not be used or considered as an offer document or solicitation of offer to buy or sell or subscribe for securities or other financial instruments. Though disseminated to all the customers simultaneously, not all customers may receive this report at the same time. KRCSSPL will not treat recipients as customers by virtue of their receiving this report. Nothing in this report constitutes investment, legal, accounting and tax advice or a representation that any investment or strategy is suitable or appropriate to your specific circumstances. The securities discussed and opinions expressed in this report may not be suitable for all investors, who must make their own investment decisions, based on their own investment objectives, financial positions and needs of specific recipient. This may not be taken in substitution for the exercise of rates, foreign exchange rates or any other reason. KRCSSPL accepts no liabilities whatsoever for any loss or damage of any kind arising out of the use of this report. As they performance is not necessarily a guide to future performance. Investors are advised to see Risk Disclosure Document to understand the risks associated before investing in the securities markets. Actual results may differ materially from those set forth in projections. Forward-looking statements are not predictions and may be subject to change without notice. Our employees in sales and herein, In reviewing these materials, you should be aware that any or all of the foregoing, among other things, may give rise to real or potential conflicts of interest.

Associates (Group Companies) of KRCSSPL might have received any commission/compensation from the companies mentioned in the report during the period preceding twelve months from the date of this report for services in respect of brokerage services or specific transaction or for products and services other than brokerage services.

KRCSSPL or its Associates (Group Companies) have not managed or co-managed public offering of securities for the subject company in the past twelve months.

KRCSSPL encourages the practice of giving independent opinion in research report preparation by the analyst and thus strives to minimize the conflict in preparation of research report. KRCSSPL or its analysts did not receive any compensation or other benefits from the companies mentioned in the report or third party in connection with preparation of the research report. Accordingly, neither KRCSSPL nor Research Analysts have any material conflict of interest at the time of publication of this report.

It is confirmed that, Parvati Rai (MBA-Finance, M.com), Head Research of this report have not received any compensation from the companies mentioned in the report in the preceding twelve months. Compensation of our Research Analysts is not based on any specific brokerage service transactions.

KRCSSPL or its associates (Group Companies) collectively or its research analyst do not hold any financial interest/beneficial ownership of more than 1% (at the end of the month immediately preceding the date of publication of the research report) in the company covered by Analyst, and has not been engaged in market making activity of the company covered by research analyst.

It is confirmed that, Parvati Rai (MBA-Finance, M.com), Head Research do not serve as an officer, director or employee of the companies mentioned in the report.

This report is not directed or intended for distribution to, or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other Jurisdiction, where such distribution, publication, availability or use would be contrary to law, regulation or which would subject KRCSSPL and affiliates to any registration or licensing requirement within such jurisdiction. The securities described herein may or may not be eligible for sale in all jurisdictions or to certain category of investors. Persons in whose possession this document may come are required to inform them of and to observe such restriction.

Please send your feedback to research.insti@krchoksey.com Visit us at <u>www.krchoksey.com</u> KRchoksey Shares and Securities PVL. Ltd Registered Office: 1102, Stock Exchange Tower, Dalai Street, Fort, Mumbai – 400 001. Phone: +91-22-6633 5000; Fax: +91-22-6633 8060. Corporate Office: ABHISHEK, 5th Floor, Link Road, Andheri (W), Mumbai – 400 053. Phone: +91-22-6695 5555; Fax: +91-22-6691 9576.

KRChoksey Research is also available on Bloomberg KRCS<GO> Thomson Reuters, Factset and Capital IQ